HDAC9 and hepatocellular carcinoma: Epigenetic agents such as DNMT inhibitors, HDAC inhibitors, and HMT inhibitors counteract these effects by reactivating chemokines and cytokines, thereby enhancing immune infiltration and restoring immune sensitivity in HCC [196].